Guide price only. Final cost is confirmed after assessment.
uFat Regenerative Therapy is a groundbreaking advancement in regenerative medicine. At London Cartilage Clinic, we utilise this cutting-edge technique, focusing on the gentle processing of adipose tissue to preserve mesenchymal Stem Cell / Medicinal Signaling Cells, enhancing the body's natural healing process. uFat therapy stands out for its ability to maintain the integrity of adipose tissue, offering superior regenerative capabilities compared to traditional methods.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
uFat focuses on gentle adipose processing to better preserve cellular architecture and stromal vascular niches that support tissue repair.
uFat and mFat are both valuable; selection depends on tissue target, required potency, and treatment objectives.
uFat is minimally invasive and designed to deliver regenerative tissue support with less disruption than more aggressive processing techniques.
At London Cartilage Clinic, uFat is integrated into a full care plan that includes diagnosis, procedural precision, and follow-up to track clinical response.
uFat therapy differs in its focus on preserving the structural integrity and cellular composition of adipose tissue. This results in a product richer in mesenchymal Stem Cell / Medicinal Signaling Cells, offering more potent regenerative properties.
uFat therapy is effective for a variety of conditions, including osteoarthritis, tissue injuries, and in cosmetic applications for tissue regeneration and anti-aging treatments.
Recovery times for uFat therapy are typically minimal, with most patients resuming normal activities within a short period. However, the specific recovery time can vary depending on the individual case.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
For active patients with cartilage defects, OATS and microfracture produce similar results at two years, but ten-year data favour OATS decisively: 14% treatment failure against 38% for microfracture—a gap reflecting tissue type, as fibrocartilage wears under athletic load whilst genuine hyaline cartilage endures.
Since its introduction in 2013, ChondroFiller has recorded zero serious adverse device effects across more than 19,000 treated cases, with a device complaint rate of 0.06%.
High-grade cartilage lesions on MRI (ICRS Grade 3–4) appear in 5–10% of symptom-free adults; cartilage grade and symptoms do not correlate, and severity alone does not determine whether surgery is required.
